Pharma · Private company
Otsuka Pharmaceutical Development & Commercialization, Inc.
Track this companyFree. Adds Otsuka Pharmaceutical Development & Commercialization, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials2516 recruiting or active
Pipeline programs24From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline24
- Antidepressant + AripiprazolePhase 3 · Major Depressive DisorderClinicalTrials.gov · fetched Nov 12, 2026
- AripiprazolePhase 3 · Autistic DisorderClinicalTrials.gov · fetched Nov 12, 2026
- AVP-786Phase 3 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- Centanafadine XRPhase 3 · Attention-deficit/Hyperactivity DisorderClinicalTrials.gov · fetched Nov 12, 2026
- JNT-517Phase 3 · Phenylketonuria (PKU)ClinicalTrials.gov · fetched Nov 12, 2026
- JNT-517Phase 3 · PhenylketonuriaClinicalTrials.gov · fetched Nov 12, 2026
- Rebamipide 1%Phase 3 · Keratoconjunctivitis SiccaClinicalTrials.gov · fetched Nov 12, 2026
- Rebamipide 2%Phase 3 · Keratoconjunctivitis SiccaClinicalTrials.gov · fetched Nov 12, 2026
- SEP-363856Phase 3 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- SEP-363856Phase 3 · Generalized Anxiety DisorderClinicalTrials.gov · fetched Nov 12, 2026
- Sibeprenlimab 400 mgPhase 3 · Immunoglobulin A NephropathyClinicalTrials.gov · fetched Nov 12, 2026
- Sibeprenlimab 400 mg s.c. Q4weeksPhase 3 · Immunoglobulin A NephropathyClinicalTrials.gov · fetched Nov 12, 2026
- tolvaptanPhase 3 · HyponatremiasClinicalTrials.gov · fetched Nov 12, 2026
- Tolvaptan SuspensionPhase 3 · Autosomal Recessive Polycystic Kidney (ARPKD)ClinicalTrials.gov · fetched Nov 12, 2026
- Tolvaptan TabletsPhase 3 · Autosomal Recessive Polycystic Kidney (ARPKD)ClinicalTrials.gov · fetched Nov 12, 2026
- AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)Phase 2 · Depressive Disorder, Treatment-ResistantClinicalTrials.gov · fetched Nov 12, 2026
- JNT-517 SuspensionPhase 2 · PhenylketonuriaClinicalTrials.gov · fetched Nov 12, 2026
- JNT-517 TabletPhase 2 · PhenylketonuriaClinicalTrials.gov · fetched Nov 12, 2026
- SibeprenlimabPhase 2 · IgA NephropathyClinicalTrials.gov · fetched Nov 12, 2026
- SibeprenlimabPhase 2 · Sjogren DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- 14C-SEP-380135Phase 1 · SchizophreniaClinicalTrials.gov · fetched Nov 12, 2026
- NDI-5001Phase 1 · Diabetes InsipidusClinicalTrials.gov · fetched Nov 12, 2026
- RepinatrabitPhase 1 · PhenylketonuriaClinicalTrials.gov · fetched Nov 12, 2026
- AripiprazoleIrritability Associated With Autistic DisorderClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- A Study to Detect the Radioactivity of 14C-SEP-380135 in Urine and Feces in Healthy Male AdultsPHASE1 · NOT_YET_RECRUITING · started Nov 1, 2026ClinicalTrials.gov NCT07455084 · fetched Nov 12, 2026
- A Trial of the Safety and Tolerability of SEP-363856 in Adults With Generalized Anxiety DisorderPHASE3 · RECRUITING · started Oct 8, 2026ClinicalTrials.gov NCT07786454 · fetched Nov 12, 2026
- A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional DysregulationPHASE3 · RECRUITING · started Sep 1, 2026ClinicalTrials.gov NCT07759154 · fetched Nov 12, 2026
- A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety DisorderPHASE3 · RECRUITING · started Aug 6, 2026ClinicalTrials.gov NCT07767903 · fetched Nov 12, 2026
- A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety DisorderPHASE3 · RECRUITING · started Jul 28, 2026ClinicalTrials.gov NCT07759128 · fetched Nov 12, 2026
- A Trial to Examine if Repinatrabit is Processed Differently in Adults With Reduced Liver or Kidney Function Compared to Adults With Normal Liver and Kidney FunctionPHASE1 · RECRUITING · started Jul 17, 2026ClinicalTrials.gov NCT07713758 · fetched Nov 12, 2026
- A Study in Adult Males With X-linked Congenital Nephrogenic Diabetes Insipidus to Test the Effects of NDI-5001 Given for Multiple Days and to Test How NDI-5001 is Tolerated and Taken up in the BodyPHASE1 · RECRUITING · started Jul 7, 2026ClinicalTrials.gov NCT07525960 · fetched Nov 12, 2026
- A Study of JNT-517 in Participants With Phenylketonuria (PKU)PHASE3 · RECRUITING · started Oct 20, 2025ClinicalTrials.gov NCT06971731 · fetched Nov 12, 2026
- A Long-Term Study of JNT-517 in Participants With PhenylketonuriaPHASE3 · RECRUITING · started Aug 11, 2025ClinicalTrials.gov NCT06628128 · fetched Nov 12, 2026
- A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren'sPHASE2 · ACTIVE_NOT_RECRUITING · started Apr 23, 2025ClinicalTrials.gov NCT06928142 · fetched Nov 12, 2026
- A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With SchizophreniaPHASE3 · ACTIVE_NOT_RECRUITING · started Feb 28, 2025ClinicalTrials.gov NCT06894212 · fetched Nov 12, 2026
- Phase 2b Open-Label Repeat Kidney Biopsy StudyPHASE2 · ACTIVE_NOT_RECRUITING · started Dec 5, 2024ClinicalTrials.gov NCT06740526 · fetched Nov 12, 2026
- A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)PHASE3 · RECRUITING · started Jan 23, 2023ClinicalTrials.gov NCT04782258 · fetched Nov 12, 2026
- First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With PhenylketonuriaPHASE1_PHASE2 · COMPLETED · started Oct 31, 2022ClinicalTrials.gov NCT05781399 · fetched Nov 12, 2026
- Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)PHASE2_PHASE3 · ENROLLING_BY_INVITATION · started Apr 5, 2022ClinicalTrials.gov NCT05248659 · fetched Nov 12, 2026
- Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)PHASE3 · ACTIVE_NOT_RECRUITING · started Mar 15, 2022ClinicalTrials.gov NCT05248646 · fetched Nov 12, 2026
- Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCLPHASE1 · ACTIVE_NOT_RECRUITING · started Feb 2, 2022ClinicalTrials.gov NCT03240211 · fetched Nov 12, 2026
- Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of SchizophreniaPHASE2_PHASE3 · TERMINATED · started Feb 15, 2019ClinicalTrials.gov NCT03896945 · fetched Nov 12, 2026
- Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant TreatmentPHASE2 · COMPLETED · started Jul 1, 2014ClinicalTrials.gov NCT02153502 · fetched Nov 12, 2026
- Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic DisorderPHASE4 · COMPLETED · started Mar 7, 2011ClinicalTrials.gov NCT01227668 · fetched Nov 12, 2026
- Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)PHASE3 · COMPLETED · started Sep 1, 2006ClinicalTrials.gov NCT00365859 · fetched Nov 12, 2026
- A Study of Adjunctive Aripiprazole in Participants With Major Depressive DisorderPHASE3 · COMPLETED · started Sep 1, 2004ClinicalTrials.gov NCT00095758 · fetched Nov 12, 2026
- A Study of Adjunctive Aripiprazole in Patients With Major Depressive DisorderPHASE3 · COMPLETED · started Jun 1, 2004ClinicalTrials.gov NCT00095823 · fetched Nov 12, 2026
- Study of Rebamipide Eye Drops to Treat Dry EyePHASE3 · COMPLETED · started May 1, 2004ClinicalTrials.gov NCT00201955 · fetched Nov 12, 2026
- "SALT Trial" Study of Ascending Levels of Tolvaptan in HyponatremiaPHASE3 · COMPLETED · started Apr 1, 2003ClinicalTrials.gov NCT00072683 · fetched Nov 12, 2026